Bailey Tianheng (688506.SH): T-Bren included in the list of breakthrough treatment varieties

Zhitong Finance App News, Baili Tianheng (688506.SH) announced that the innovative biopharmaceutical T-Bren (HER2 ADC) independently developed by the company is an innovative ADC targeting HER2. It has best-in-class (best-in-class) potential and has shown significant anti-tumor efficacy in clinical trials. Its plan for patients with locally advanced or metastatic biliary cancer that has failed to be treated with platinum-containing chemotherapy with HER2 expression has been included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the State Drug Administration (“Drug Review Center”) , The announcement was completed recently.

Up to now, T-Bren is conducting 20 clinical trials at home and abroad, including 9 phase III, 1 phase II/III, 4 phase II, 3 phase I/II, and 3 phase I clinical trials, covering first-line and second-line HER2-positive breast cancer, HER2-positive breast cancer post-operative support, new adjuvant treatment for HER2-positive breast cancer, HER2-positive breast cancer, HER2-positive gastric cancer or gastroesophageal adenocarcinoma, her2 mutated non-squamous non-small cell lung cancer, and lung cancer, gastrointestinal tumors, and urinary system tumors Various adaptations such as gynecological oncology disease.

In addition to this new inclusion, in November 2025, t-Bren's plan for patients with HER2-positive locally advanced or metastatic gastric cancer or gastroesophageal conjunctive adenocarcinoma who have previously failed to be treated with first-line anti-HER2 treatment and first-line standardized treatment regimens was included in the Drug Review Center's list of breakthrough treatment categories and completed publicity.